釓類對比劑蓄積相關文獻

  1. Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities. McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL, Williamson EE, Eckel LJ. Radiology. 2017 Jun 27:161595. doi: 0.1148/radiol.2017161595

  2. Gadolinium deposition in the brain: summary of evidence and recommendations.Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB; International Society for Magnetic Resonance in Medicine. Lancet Neurol. 2017 Jul;16(7):564-570. doi: 10.1016/S1474-4422(17)30158-8. 

  3. Gadolinium deposition: practical guidelines in the face of uncertainty. Terashima KH, Reich DS. Lancet Neurol. 2017 Jul;16(7):495-497. doi: 10.1016/S1474-4422(17)30174-6. 

  4. Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study. Tibussek D, Rademacher C, Caspers J, Turowski B, Schaper J, Antoch G, Klee D. Radiology. 2017 Jun 21:161151. doi: 10.1148/radiol.2017161151

  5. Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates.McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, Kadirvel R, Eckel LJ, Kallmes DF. Radiology. 2017 Jun 19:161594. doi: 10.1148/radiol.2017161594. 

  6. Sodium MRI of T1 High Signal Intensity in the Dentate Nucleus due to Gadolinium Deposition in Multiple Sclerosis. Eisele P, Konstandin S, Szabo K, Ong M, Zöllner F, Schad LR, Schoenberg SO, Gass A. J Neuroimaging. 2017 Jun 1. doi: 10.1111/jon.12448 

  7. Intracranial Gadolinium Deposition Following Gadodiamide-Enhanced Magnetic Resonance Imaging in Pediatric Patients: A Case-Control Study.

    McDonald JS, McDonald RJ, Jentoft ME, Paolini MA, Murray DL, Kallmes DF, Eckel LJ. JAMA Pediatr. 2017 Jul 1;171(7):705-707. doi: 10.1001/jamapediatrics.2017.0264.

  8. Gadolinium Retention and Toxicity-An Update. Ramalho M, Ramalho J, Burke LM, Semelka RC.Adv Chronic Kidney Dis. 2017 May;24(3):138-146. doi: 10.1053/j.ackd.2017.03.004

  9. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Runge VM Invest Radiol. 2017 Jun;52(6):317-323. doi: 10.1097/RLI.0000000000000374.

  10. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A, Pietsch H.

    Invest Radiol. 2017 Jun;52(6):324-333. doi: 10.1097/RLI.0000000000000344.

  11. Intracranial Deposition of Intravenous Gadolinium Contrast: A Literature Review.Franco J. Radiol Technol. 2017 Mar;88(4):435-439. No abstract available. 

  12. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America. Mithal LB, Patel PS, Mithal D, Palac HL, Rozenfeld MN. Pediatr Radiol. 2017 May;47(6):657-664. doi: 10.1007/s00247-017-3810-4. Epub 2017 Mar 10.

  13. Effect of Gadolinium Deposition on 18F-FDG PET/CT of Dentate Nucleus and Globus Pallidus. Naganawa S.

    J Nucl Med Technol. 2017 Jun;45(2):173. doi: 10.2967/jnmt.116.187591

  14. Reply: Effect of Gadolinium Deposition on 18F-FDG PET/CT of Dentate Nucleus and Globus Pallidus. Osman M, Turner A.

    J Nucl Med Technol. 2017 Jun;45(2):173. doi: 10.2967/jnmt.117.191577. Epub 2017 Mar 9

  15. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review. Olchowy C, Cebulski K, Łasecki M, Chaber R, Olchowy A, Kałwak K, Zaleska-Dorobisz U. PLoS One. 2017 Feb 10;12(2):e0171704. doi: 10.1371/journal.pone.0171704. 

  16. The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes. Prybylski JP, Semelka RC, Jay M. Magn Reson Imaging. 2017 May;38:145-151. doi: 10.1016/j.mri.2017.01.006.

  17. Gadolinium-based contrast agents: A comprehensive risk assessment. Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. J Magn Reson Imaging. 2017 Jan 13. doi: 10.1002/jmri.25625.

  18. Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model. Bae S, Lee HJ, Han K, Park YW, Choi YS, Ahn SS, Kim J, Lee SK. Eur Radiol. 2017 Aug;27(8):3353-3361. doi: 10.1007/s00330-016-4724-5

  19. Do Gadolinium-Based Contrast Agents Affect 18F-FDG PET/CT Uptake in the Dentate Nucleus and the Globus Pallidus? A Pilot Study.

    Bauer K, Lathrum A, Raslan O, Kelly PV, Zhou Y, Hewing D, Botkin C, Turner JA, Osman M. J Nucl Med Technol. 2017 Mar;45(1):30-33. doi: 0.2967/jnmt.116.180844.

  20. Gadolinium deposition in the brain. Kanda T, Nakai Y, Oba H, Toyoda K, Kitajima K, Furui S. Magn Reson Imaging. 2016 Dec;34(10):1346-1350. doi: 10.1016/j.mri.2016.08.024. Epub 2016 Sep 8. Review

 

聯絡我們

普樂可醫藥股份有限公司 地址 : 台北市民生東路一段58號11樓 電話 : (02) 2521-0566
傳真 : (02) 2571-0157
p5418173@ms17.hinet.net